Global Companion Diagnostics for Oncology Market Research Report 2023
Companion diagnostic (CDx) is a diagnostic testing kit majorly used by pharmaceutical companies for the development of personalized medicine. CDx tests provide information about the effective use of a corresponding therapeutic product by analyzing the genetic material. With the rise in cancer prevalence, coupled with increasing strategic initiatives, there has been a huge demand for companion diagnostics in the oncology area.
According to QYResearch’s new survey, global Companion Diagnostics for Oncology market is projected to reach US$ 8392.9 million in 2029, increasing from US$ 4101 million in 2022, with the CAGR of 10.8% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Companion Diagnostics for Oncology market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Companion Diagnostics for Oncology market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
According to QYResearch’s new survey, global Companion Diagnostics for Oncology market is projected to reach US$ 8392.9 million in 2029, increasing from US$ 4101 million in 2022, with the CAGR of 10.8% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Companion Diagnostics for Oncology market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Companion Diagnostics for Oncology market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
- Agilent Technologies
- Illumina
- Roche
- BioMйrieux
- Foundation Medicine
- ArcherDX
- Qiagen
- Thermo Fisher Scientific
- Amoy Diagnostics
- Abbott
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Pharmaceutical and Biopharmaceutical Companies
- Contract Research Organizations
- Laboratories
- Others
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Companion Diagnostics for Oncology Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Polymerase Chain Reaction (PCR)
1.2.3 Next-Generation Sequencing (NGS)
1.3 Market by Application
1.3.1 Global Companion Diagnostics for Oncology Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Pharmaceutical and Biopharmaceutical Companies
1.3.3 Contract Research Organizations
1.3.4 Laboratories
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Companion Diagnostics for Oncology Market Perspective (2018-2029)
2.2 Companion Diagnostics for Oncology Growth Trends by Region
2.2.1 Global Companion Diagnostics for Oncology Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Companion Diagnostics for Oncology Historic Market Size by Region (2018-2023)
2.2.3 Companion Diagnostics for Oncology Forecasted Market Size by Region (2024-2029)
2.3 Companion Diagnostics for Oncology Market Dynamics
2.3.1 Companion Diagnostics for Oncology Industry Trends
2.3.2 Companion Diagnostics for Oncology Market Drivers
2.3.3 Companion Diagnostics for Oncology Market Challenges
2.3.4 Companion Diagnostics for Oncology Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Companion Diagnostics for Oncology Players by Revenue
3.1.1 Global Top Companion Diagnostics for Oncology Players by Revenue (2018-2023)
3.1.2 Global Companion Diagnostics for Oncology Revenue Market Share by Players (2018-2023)
3.2 Global Companion Diagnostics for Oncology Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Companion Diagnostics for Oncology Revenue
3.4 Global Companion Diagnostics for Oncology Market Concentration Ratio
3.4.1 Global Companion Diagnostics for Oncology Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Companion Diagnostics for Oncology Revenue in 2022
3.5 Companion Diagnostics for Oncology Key Players Head office and Area Served
3.6 Key Players Companion Diagnostics for Oncology Product Solution and Service
3.7 Date of Enter into Companion Diagnostics for Oncology Market
3.8 Mergers & Acquisitions, Expansion Plans
4 COMPANION DIAGNOSTICS FOR ONCOLOGY BREAKDOWN DATA BY TYPE
4.1 Global Companion Diagnostics for Oncology Historic Market Size by Type (2018-2023)
4.2 Global Companion Diagnostics for Oncology Forecasted Market Size by Type (2024-2029)
5 COMPANION DIAGNOSTICS FOR ONCOLOGY BREAKDOWN DATA BY APPLICATION
5.1 Global Companion Diagnostics for Oncology Historic Market Size by Application (2018-2023)
5.2 Global Companion Diagnostics for Oncology Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Companion Diagnostics for Oncology Market Size (2018-2029)
6.2 North America Companion Diagnostics for Oncology Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Companion Diagnostics for Oncology Market Size by Country (2018-2023)
6.4 North America Companion Diagnostics for Oncology Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe Companion Diagnostics for Oncology Market Size (2018-2029)
7.2 Europe Companion Diagnostics for Oncology Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Companion Diagnostics for Oncology Market Size by Country (2018-2023)
7.4 Europe Companion Diagnostics for Oncology Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific Companion Diagnostics for Oncology Market Size (2018-2029)
8.2 Asia-Pacific Companion Diagnostics for Oncology Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Companion Diagnostics for Oncology Market Size by Region (2018-2023)
8.4 Asia-Pacific Companion Diagnostics for Oncology Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America Companion Diagnostics for Oncology Market Size (2018-2029)
9.2 Latin America Companion Diagnostics for Oncology Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Companion Diagnostics for Oncology Market Size by Country (2018-2023)
9.4 Latin America Companion Diagnostics for Oncology Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Companion Diagnostics for Oncology Market Size (2018-2029)
10.2 Middle East & Africa Companion Diagnostics for Oncology Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Companion Diagnostics for Oncology Market Size by Country (2018-2023)
10.4 Middle East & Africa Companion Diagnostics for Oncology Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 Agilent Technologies
11.1.1 Agilent Technologies Company Detail
11.1.2 Agilent Technologies Business Overview
11.1.3 Agilent Technologies Companion Diagnostics for Oncology Introduction
11.1.4 Agilent Technologies Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.1.5 Agilent Technologies Recent Development
11.2 Illumina
11.2.1 Illumina Company Detail
11.2.2 Illumina Business Overview
11.2.3 Illumina Companion Diagnostics for Oncology Introduction
11.2.4 Illumina Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.2.5 Illumina Recent Development
11.3 Roche
11.3.1 Roche Company Detail
11.3.2 Roche Business Overview
11.3.3 Roche Companion Diagnostics for Oncology Introduction
11.3.4 Roche Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.3.5 Roche Recent Development
11.4 BioMйrieux
11.4.1 BioMйrieux Company Detail
11.4.2 BioMйrieux Business Overview
11.4.3 BioMйrieux Companion Diagnostics for Oncology Introduction
11.4.4 BioMйrieux Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.4.5 BioMйrieux Recent Development
11.5 Foundation Medicine
11.5.1 Foundation Medicine Company Detail
11.5.2 Foundation Medicine Business Overview
11.5.3 Foundation Medicine Companion Diagnostics for Oncology Introduction
11.5.4 Foundation Medicine Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.5.5 Foundation Medicine Recent Development
11.6 ArcherDX
11.6.1 ArcherDX Company Detail
11.6.2 ArcherDX Business Overview
11.6.3 ArcherDX Companion Diagnostics for Oncology Introduction
11.6.4 ArcherDX Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.6.5 ArcherDX Recent Development
11.7 Qiagen
11.7.1 Qiagen Company Detail
11.7.2 Qiagen Business Overview
11.7.3 Qiagen Companion Diagnostics for Oncology Introduction
11.7.4 Qiagen Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.7.5 Qiagen Recent Development
11.8 Thermo Fisher Scientific
11.8.1 Thermo Fisher Scientific Company Detail
11.8.2 Thermo Fisher Scientific Business Overview
11.8.3 Thermo Fisher Scientific Companion Diagnostics for Oncology Introduction
11.8.4 Thermo Fisher Scientific Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.8.5 Thermo Fisher Scientific Recent Development
11.9 Amoy Diagnostics
11.9.1 Amoy Diagnostics Company Detail
11.9.2 Amoy Diagnostics Business Overview
11.9.3 Amoy Diagnostics Companion Diagnostics for Oncology Introduction
11.9.4 Amoy Diagnostics Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.9.5 Amoy Diagnostics Recent Development
11.10 Abbott
11.10.1 Abbott Company Detail
11.10.2 Abbott Business Overview
11.10.3 Abbott Companion Diagnostics for Oncology Introduction
11.10.4 Abbott Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.10.5 Abbott Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Companion Diagnostics for Oncology Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Polymerase Chain Reaction (PCR)
1.2.3 Next-Generation Sequencing (NGS)
1.3 Market by Application
1.3.1 Global Companion Diagnostics for Oncology Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Pharmaceutical and Biopharmaceutical Companies
1.3.3 Contract Research Organizations
1.3.4 Laboratories
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Companion Diagnostics for Oncology Market Perspective (2018-2029)
2.2 Companion Diagnostics for Oncology Growth Trends by Region
2.2.1 Global Companion Diagnostics for Oncology Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Companion Diagnostics for Oncology Historic Market Size by Region (2018-2023)
2.2.3 Companion Diagnostics for Oncology Forecasted Market Size by Region (2024-2029)
2.3 Companion Diagnostics for Oncology Market Dynamics
2.3.1 Companion Diagnostics for Oncology Industry Trends
2.3.2 Companion Diagnostics for Oncology Market Drivers
2.3.3 Companion Diagnostics for Oncology Market Challenges
2.3.4 Companion Diagnostics for Oncology Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Companion Diagnostics for Oncology Players by Revenue
3.1.1 Global Top Companion Diagnostics for Oncology Players by Revenue (2018-2023)
3.1.2 Global Companion Diagnostics for Oncology Revenue Market Share by Players (2018-2023)
3.2 Global Companion Diagnostics for Oncology Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Companion Diagnostics for Oncology Revenue
3.4 Global Companion Diagnostics for Oncology Market Concentration Ratio
3.4.1 Global Companion Diagnostics for Oncology Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Companion Diagnostics for Oncology Revenue in 2022
3.5 Companion Diagnostics for Oncology Key Players Head office and Area Served
3.6 Key Players Companion Diagnostics for Oncology Product Solution and Service
3.7 Date of Enter into Companion Diagnostics for Oncology Market
3.8 Mergers & Acquisitions, Expansion Plans
4 COMPANION DIAGNOSTICS FOR ONCOLOGY BREAKDOWN DATA BY TYPE
4.1 Global Companion Diagnostics for Oncology Historic Market Size by Type (2018-2023)
4.2 Global Companion Diagnostics for Oncology Forecasted Market Size by Type (2024-2029)
5 COMPANION DIAGNOSTICS FOR ONCOLOGY BREAKDOWN DATA BY APPLICATION
5.1 Global Companion Diagnostics for Oncology Historic Market Size by Application (2018-2023)
5.2 Global Companion Diagnostics for Oncology Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Companion Diagnostics for Oncology Market Size (2018-2029)
6.2 North America Companion Diagnostics for Oncology Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Companion Diagnostics for Oncology Market Size by Country (2018-2023)
6.4 North America Companion Diagnostics for Oncology Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe Companion Diagnostics for Oncology Market Size (2018-2029)
7.2 Europe Companion Diagnostics for Oncology Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Companion Diagnostics for Oncology Market Size by Country (2018-2023)
7.4 Europe Companion Diagnostics for Oncology Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific Companion Diagnostics for Oncology Market Size (2018-2029)
8.2 Asia-Pacific Companion Diagnostics for Oncology Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Companion Diagnostics for Oncology Market Size by Region (2018-2023)
8.4 Asia-Pacific Companion Diagnostics for Oncology Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America Companion Diagnostics for Oncology Market Size (2018-2029)
9.2 Latin America Companion Diagnostics for Oncology Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Companion Diagnostics for Oncology Market Size by Country (2018-2023)
9.4 Latin America Companion Diagnostics for Oncology Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Companion Diagnostics for Oncology Market Size (2018-2029)
10.2 Middle East & Africa Companion Diagnostics for Oncology Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Companion Diagnostics for Oncology Market Size by Country (2018-2023)
10.4 Middle East & Africa Companion Diagnostics for Oncology Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 Agilent Technologies
11.1.1 Agilent Technologies Company Detail
11.1.2 Agilent Technologies Business Overview
11.1.3 Agilent Technologies Companion Diagnostics for Oncology Introduction
11.1.4 Agilent Technologies Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.1.5 Agilent Technologies Recent Development
11.2 Illumina
11.2.1 Illumina Company Detail
11.2.2 Illumina Business Overview
11.2.3 Illumina Companion Diagnostics for Oncology Introduction
11.2.4 Illumina Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.2.5 Illumina Recent Development
11.3 Roche
11.3.1 Roche Company Detail
11.3.2 Roche Business Overview
11.3.3 Roche Companion Diagnostics for Oncology Introduction
11.3.4 Roche Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.3.5 Roche Recent Development
11.4 BioMйrieux
11.4.1 BioMйrieux Company Detail
11.4.2 BioMйrieux Business Overview
11.4.3 BioMйrieux Companion Diagnostics for Oncology Introduction
11.4.4 BioMйrieux Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.4.5 BioMйrieux Recent Development
11.5 Foundation Medicine
11.5.1 Foundation Medicine Company Detail
11.5.2 Foundation Medicine Business Overview
11.5.3 Foundation Medicine Companion Diagnostics for Oncology Introduction
11.5.4 Foundation Medicine Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.5.5 Foundation Medicine Recent Development
11.6 ArcherDX
11.6.1 ArcherDX Company Detail
11.6.2 ArcherDX Business Overview
11.6.3 ArcherDX Companion Diagnostics for Oncology Introduction
11.6.4 ArcherDX Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.6.5 ArcherDX Recent Development
11.7 Qiagen
11.7.1 Qiagen Company Detail
11.7.2 Qiagen Business Overview
11.7.3 Qiagen Companion Diagnostics for Oncology Introduction
11.7.4 Qiagen Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.7.5 Qiagen Recent Development
11.8 Thermo Fisher Scientific
11.8.1 Thermo Fisher Scientific Company Detail
11.8.2 Thermo Fisher Scientific Business Overview
11.8.3 Thermo Fisher Scientific Companion Diagnostics for Oncology Introduction
11.8.4 Thermo Fisher Scientific Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.8.5 Thermo Fisher Scientific Recent Development
11.9 Amoy Diagnostics
11.9.1 Amoy Diagnostics Company Detail
11.9.2 Amoy Diagnostics Business Overview
11.9.3 Amoy Diagnostics Companion Diagnostics for Oncology Introduction
11.9.4 Amoy Diagnostics Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.9.5 Amoy Diagnostics Recent Development
11.10 Abbott
11.10.1 Abbott Company Detail
11.10.2 Abbott Business Overview
11.10.3 Abbott Companion Diagnostics for Oncology Introduction
11.10.4 Abbott Revenue in Companion Diagnostics for Oncology Business (2018-2023)
11.10.5 Abbott Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
LIST OF TABLES
Table 1. Global Companion Diagnostics for Oncology Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Polymerase Chain Reaction (PCR)
Table 3. Key Players of Next-Generation Sequencing (NGS)
Table 4. Global Companion Diagnostics for Oncology Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 5. Global Companion Diagnostics for Oncology Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Companion Diagnostics for Oncology Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Companion Diagnostics for Oncology Market Share by Region (2018-2023)
Table 8. Global Companion Diagnostics for Oncology Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Companion Diagnostics for Oncology Market Share by Region (2024-2029)
Table 10. Companion Diagnostics for Oncology Market Trends
Table 11. Companion Diagnostics for Oncology Market Drivers
Table 12. Companion Diagnostics for Oncology Market Challenges
Table 13. Companion Diagnostics for Oncology Market Restraints
Table 14. Global Companion Diagnostics for Oncology Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Companion Diagnostics for Oncology Market Share by Players (2018-2023)
Table 16. Global Top Companion Diagnostics for Oncology Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Companion Diagnostics for Oncology as of 2022)
Table 17. Ranking of Global Top Companion Diagnostics for Oncology Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Companion Diagnostics for Oncology Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Companion Diagnostics for Oncology Product Solution and Service
Table 21. Date of Enter into Companion Diagnostics for Oncology Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Companion Diagnostics for Oncology Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Companion Diagnostics for Oncology Revenue Market Share by Type (2018-2023)
Table 25. Global Companion Diagnostics for Oncology Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Companion Diagnostics for Oncology Revenue Market Share by Type (2024-2029)
Table 27. Global Companion Diagnostics for Oncology Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Companion Diagnostics for Oncology Revenue Market Share by Application (2018-2023)
Table 29. Global Companion Diagnostics for Oncology Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Companion Diagnostics for Oncology Revenue Market Share by Application (2024-2029)
Table 31. North America Companion Diagnostics for Oncology Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 32. North America Companion Diagnostics for Oncology Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Companion Diagnostics for Oncology Market Size by Country (2024-2029) & (US$ Million)
Table 34. Europe Companion Diagnostics for Oncology Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. Europe Companion Diagnostics for Oncology Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Companion Diagnostics for Oncology Market Size by Country (2024-2029) & (US$ Million)
Table 37. Asia-Pacific Companion Diagnostics for Oncology Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 38. Asia-Pacific Companion Diagnostics for Oncology Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Companion Diagnostics for Oncology Market Size by Region (2024-2029) & (US$ Million)
Table 40. Latin America Companion Diagnostics for Oncology Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 41. Latin America Companion Diagnostics for Oncology Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America Companion Diagnostics for Oncology Market Size by Country (2024-2029) & (US$ Million)
Table 43. Middle East & Africa Companion Diagnostics for Oncology Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Middle East & Africa Companion Diagnostics for Oncology Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa Companion Diagnostics for Oncology Market Size by Country (2024-2029) & (US$ Million)
Table 46. Agilent Technologies Company Detail
Table 47. Agilent Technologies Business Overview
Table 48. Agilent Technologies Companion Diagnostics for Oncology Product
Table 49. Agilent Technologies Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 50. Agilent Technologies Recent Development
Table 51. Illumina Company Detail
Table 52. Illumina Business Overview
Table 53. Illumina Companion Diagnostics for Oncology Product
Table 54. Illumina Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 55. Illumina Recent Development
Table 56. Roche Company Detail
Table 57. Roche Business Overview
Table 58. Roche Companion Diagnostics for Oncology Product
Table 59. Roche Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 60. Roche Recent Development
Table 61. BioMйrieux Company Detail
Table 62. BioMйrieux Business Overview
Table 63. BioMйrieux Companion Diagnostics for Oncology Product
Table 64. BioMйrieux Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 65. BioMйrieux Recent Development
Table 66. Foundation Medicine Company Detail
Table 67. Foundation Medicine Business Overview
Table 68. Foundation Medicine Companion Diagnostics for Oncology Product
Table 69. Foundation Medicine Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 70. Foundation Medicine Recent Development
Table 71. ArcherDX Company Detail
Table 72. ArcherDX Business Overview
Table 73. ArcherDX Companion Diagnostics for Oncology Product
Table 74. ArcherDX Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 75. ArcherDX Recent Development
Table 76. Qiagen Company Detail
Table 77. Qiagen Business Overview
Table 78. Qiagen Companion Diagnostics for Oncology Product
Table 79. Qiagen Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 80. Qiagen Recent Development
Table 81. Thermo Fisher Scientific Company Detail
Table 82. Thermo Fisher Scientific Business Overview
Table 83. Thermo Fisher Scientific Companion Diagnostics for Oncology Product
Table 84. Thermo Fisher Scientific Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 85. Thermo Fisher Scientific Recent Development
Table 86. Amoy Diagnostics Company Detail
Table 87. Amoy Diagnostics Business Overview
Table 88. Amoy Diagnostics Companion Diagnostics for Oncology Product
Table 89. Amoy Diagnostics Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 90. Amoy Diagnostics Recent Development
Table 91. Abbott Company Detail
Table 92. Abbott Business Overview
Table 93. Abbott Companion Diagnostics for Oncology Product
Table 94. Abbott Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 95. Abbott Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
Table 1. Global Companion Diagnostics for Oncology Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Polymerase Chain Reaction (PCR)
Table 3. Key Players of Next-Generation Sequencing (NGS)
Table 4. Global Companion Diagnostics for Oncology Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 5. Global Companion Diagnostics for Oncology Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Companion Diagnostics for Oncology Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Companion Diagnostics for Oncology Market Share by Region (2018-2023)
Table 8. Global Companion Diagnostics for Oncology Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Companion Diagnostics for Oncology Market Share by Region (2024-2029)
Table 10. Companion Diagnostics for Oncology Market Trends
Table 11. Companion Diagnostics for Oncology Market Drivers
Table 12. Companion Diagnostics for Oncology Market Challenges
Table 13. Companion Diagnostics for Oncology Market Restraints
Table 14. Global Companion Diagnostics for Oncology Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Companion Diagnostics for Oncology Market Share by Players (2018-2023)
Table 16. Global Top Companion Diagnostics for Oncology Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Companion Diagnostics for Oncology as of 2022)
Table 17. Ranking of Global Top Companion Diagnostics for Oncology Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Companion Diagnostics for Oncology Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Companion Diagnostics for Oncology Product Solution and Service
Table 21. Date of Enter into Companion Diagnostics for Oncology Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Companion Diagnostics for Oncology Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Companion Diagnostics for Oncology Revenue Market Share by Type (2018-2023)
Table 25. Global Companion Diagnostics for Oncology Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Companion Diagnostics for Oncology Revenue Market Share by Type (2024-2029)
Table 27. Global Companion Diagnostics for Oncology Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Companion Diagnostics for Oncology Revenue Market Share by Application (2018-2023)
Table 29. Global Companion Diagnostics for Oncology Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Companion Diagnostics for Oncology Revenue Market Share by Application (2024-2029)
Table 31. North America Companion Diagnostics for Oncology Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 32. North America Companion Diagnostics for Oncology Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Companion Diagnostics for Oncology Market Size by Country (2024-2029) & (US$ Million)
Table 34. Europe Companion Diagnostics for Oncology Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. Europe Companion Diagnostics for Oncology Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Companion Diagnostics for Oncology Market Size by Country (2024-2029) & (US$ Million)
Table 37. Asia-Pacific Companion Diagnostics for Oncology Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 38. Asia-Pacific Companion Diagnostics for Oncology Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Companion Diagnostics for Oncology Market Size by Region (2024-2029) & (US$ Million)
Table 40. Latin America Companion Diagnostics for Oncology Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 41. Latin America Companion Diagnostics for Oncology Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America Companion Diagnostics for Oncology Market Size by Country (2024-2029) & (US$ Million)
Table 43. Middle East & Africa Companion Diagnostics for Oncology Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Middle East & Africa Companion Diagnostics for Oncology Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa Companion Diagnostics for Oncology Market Size by Country (2024-2029) & (US$ Million)
Table 46. Agilent Technologies Company Detail
Table 47. Agilent Technologies Business Overview
Table 48. Agilent Technologies Companion Diagnostics for Oncology Product
Table 49. Agilent Technologies Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 50. Agilent Technologies Recent Development
Table 51. Illumina Company Detail
Table 52. Illumina Business Overview
Table 53. Illumina Companion Diagnostics for Oncology Product
Table 54. Illumina Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 55. Illumina Recent Development
Table 56. Roche Company Detail
Table 57. Roche Business Overview
Table 58. Roche Companion Diagnostics for Oncology Product
Table 59. Roche Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 60. Roche Recent Development
Table 61. BioMйrieux Company Detail
Table 62. BioMйrieux Business Overview
Table 63. BioMйrieux Companion Diagnostics for Oncology Product
Table 64. BioMйrieux Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 65. BioMйrieux Recent Development
Table 66. Foundation Medicine Company Detail
Table 67. Foundation Medicine Business Overview
Table 68. Foundation Medicine Companion Diagnostics for Oncology Product
Table 69. Foundation Medicine Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 70. Foundation Medicine Recent Development
Table 71. ArcherDX Company Detail
Table 72. ArcherDX Business Overview
Table 73. ArcherDX Companion Diagnostics for Oncology Product
Table 74. ArcherDX Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 75. ArcherDX Recent Development
Table 76. Qiagen Company Detail
Table 77. Qiagen Business Overview
Table 78. Qiagen Companion Diagnostics for Oncology Product
Table 79. Qiagen Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 80. Qiagen Recent Development
Table 81. Thermo Fisher Scientific Company Detail
Table 82. Thermo Fisher Scientific Business Overview
Table 83. Thermo Fisher Scientific Companion Diagnostics for Oncology Product
Table 84. Thermo Fisher Scientific Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 85. Thermo Fisher Scientific Recent Development
Table 86. Amoy Diagnostics Company Detail
Table 87. Amoy Diagnostics Business Overview
Table 88. Amoy Diagnostics Companion Diagnostics for Oncology Product
Table 89. Amoy Diagnostics Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 90. Amoy Diagnostics Recent Development
Table 91. Abbott Company Detail
Table 92. Abbott Business Overview
Table 93. Abbott Companion Diagnostics for Oncology Product
Table 94. Abbott Revenue in Companion Diagnostics for Oncology Business (2018-2023) & (US$ Million)
Table 95. Abbott Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Companion Diagnostics for Oncology Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Companion Diagnostics for Oncology Market Share by Type: 2022 VS 2029
Figure 3. Polymerase Chain Reaction (PCR) Features
Figure 4. Next-Generation Sequencing (NGS) Features
Figure 5. Global Companion Diagnostics for Oncology Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 6. Global Companion Diagnostics for Oncology Market Share by Application: 2022 VS 2029
Figure 7. Pharmaceutical and Biopharmaceutical Companies Case Studies
Figure 8. Contract Research Organizations Case Studies
Figure 9. Laboratories Case Studies
Figure 10. Others Case Studies
Figure 11. Companion Diagnostics for Oncology Report Years Considered
Figure 12. Global Companion Diagnostics for Oncology Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 13. Global Companion Diagnostics for Oncology Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Companion Diagnostics for Oncology Market Share by Region: 2022 VS 2029
Figure 15. Global Companion Diagnostics for Oncology Market Share by Players in 2022
Figure 16. Global Top Companion Diagnostics for Oncology Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Companion Diagnostics for Oncology as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Companion Diagnostics for Oncology Revenue in 2022
Figure 18. North America Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 19. North America Companion Diagnostics for Oncology Market Share by Country (2018-2029)
Figure 20. United States Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. Canada Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Europe Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Europe Companion Diagnostics for Oncology Market Share by Country (2018-2029)
Figure 24. Germany Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. France Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. U.K. Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Italy Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Russia Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Nordic Countries Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Asia-Pacific Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Asia-Pacific Companion Diagnostics for Oncology Market Share by Region (2018-2029)
Figure 32. China Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Japan Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. South Korea Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Southeast Asia Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. India Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Australia Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Latin America Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Latin America Companion Diagnostics for Oncology Market Share by Country (2018-2029)
Figure 40. Mexico Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Brazil Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Middle East & Africa Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Middle East & Africa Companion Diagnostics for Oncology Market Share by Country (2018-2029)
Figure 44. Turkey Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Saudi Arabia Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Agilent Technologies Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 47. Illumina Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 48. Roche Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 49. BioMйrieux Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 50. Foundation Medicine Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 51. ArcherDX Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 52. Qiagen Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 53. Thermo Fisher Scientific Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 54. Amoy Diagnostics Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 55. Abbott Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
Figure 1. Global Companion Diagnostics for Oncology Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Companion Diagnostics for Oncology Market Share by Type: 2022 VS 2029
Figure 3. Polymerase Chain Reaction (PCR) Features
Figure 4. Next-Generation Sequencing (NGS) Features
Figure 5. Global Companion Diagnostics for Oncology Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 6. Global Companion Diagnostics for Oncology Market Share by Application: 2022 VS 2029
Figure 7. Pharmaceutical and Biopharmaceutical Companies Case Studies
Figure 8. Contract Research Organizations Case Studies
Figure 9. Laboratories Case Studies
Figure 10. Others Case Studies
Figure 11. Companion Diagnostics for Oncology Report Years Considered
Figure 12. Global Companion Diagnostics for Oncology Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 13. Global Companion Diagnostics for Oncology Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Companion Diagnostics for Oncology Market Share by Region: 2022 VS 2029
Figure 15. Global Companion Diagnostics for Oncology Market Share by Players in 2022
Figure 16. Global Top Companion Diagnostics for Oncology Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Companion Diagnostics for Oncology as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Companion Diagnostics for Oncology Revenue in 2022
Figure 18. North America Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 19. North America Companion Diagnostics for Oncology Market Share by Country (2018-2029)
Figure 20. United States Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. Canada Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Europe Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Europe Companion Diagnostics for Oncology Market Share by Country (2018-2029)
Figure 24. Germany Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. France Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. U.K. Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Italy Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Russia Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Nordic Countries Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Asia-Pacific Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Asia-Pacific Companion Diagnostics for Oncology Market Share by Region (2018-2029)
Figure 32. China Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Japan Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. South Korea Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Southeast Asia Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. India Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Australia Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Latin America Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Latin America Companion Diagnostics for Oncology Market Share by Country (2018-2029)
Figure 40. Mexico Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Brazil Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Middle East & Africa Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Middle East & Africa Companion Diagnostics for Oncology Market Share by Country (2018-2029)
Figure 44. Turkey Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Saudi Arabia Companion Diagnostics for Oncology Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Agilent Technologies Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 47. Illumina Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 48. Roche Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 49. BioMйrieux Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 50. Foundation Medicine Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 51. ArcherDX Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 52. Qiagen Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 53. Thermo Fisher Scientific Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 54. Amoy Diagnostics Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 55. Abbott Revenue Growth Rate in Companion Diagnostics for Oncology Business (2018-2023)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
